Preclinical data presented for the first time demonstrated successful manufacture and functional activity of KYV-101 in the blood of patients with systemic lupus erythematosus (SLE), commonly known as lupus
Research conducted in partnership with University of Erlangen
Data to be presented in poster session and industry-sponsored symposium about CAR T-cell therapy in B-cell driven autoimmune diseases
EMERYVILLE, Calif., May 24, 2023 — Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced it will present new preclinical findings on KYV-101. KYV-101 is a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy designed to deplete B cells, including autoreactive B cells in autoimmune disease patients. The data will be presented at a poster session and at an industry-sponsored symposium at the 2023 European Congress of Rheumatology (EULAR), being held May 31-June 2, 2023, in Milan, Italy.
“These data demonstrated strong CAR-mediated activity in vitro of KYV-101 CAR T cells derived from patients with lupus, a key prerequisite for positive outcomes,” said Peter Maag, Ph.D., chief executive officer (CEO) of Kyverna.
The data, generated in collaboration with scientists at the Friedrich-Alexander University, Erlangen-Nürnberg, Germany, showed KYV-101 CAR T cells derived from patients with systemic lupus erythematosus (SLE), SLE with lupus nephritis (LN), or rheumatoid arthritis, demonstrated strong CAR-mediated and CD19-dependent activity against autologous B cells. Of note, SLE and SLE with LN-derived KYV-101 CAR T cells produced less cytokines in response to autologous B cells compared to KYV-101 CAR T cells derived from healthy donors.
KYV-101, A Fully Human CD19 CAR T cell Generated from Autoimmune Patient Lymphocytes, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B cells
Abstract Number: 6228
Poster Number: POS0007
Session: Wednesday Poster Session
Presenter: Dominic Borie, M.D, Ph.D., president of R&D at Kyverna Therapeutics
Date/Time: Thursday, June 1, 2023; 12:00 p.m. – 1:30 p.m. CEST
Kyverna Satellite Symposium
CAR T-Cell Therapy in B-Cell Driven Autoimmune Diseases
The company is hosting an industry-sponsored symposium featuring key thought leaders and senior leaders from Kyverna. The session will be part of the EULAR satellite symposia, and will take place on Friday, June 2, 2023, from 8:15 a.m. — 9:30 a.m. CEST.
The symposium will focus on understanding the role of B cells in autoimmune diseases and the rationale for pursuing deeper B-cell depletion through CAR T-cell therapy. There will be a review of the clinical data in the use of anti-CD19 CAR T-cell therapy in SLE and other autoimmune diseases. Speakers and panelists will also review lessons learned from CD19 CAR T therapy in oncology and how these lessons inform the development of KYV-101 for autoimmune diseases.
- Georg Schett, M.D., vice president of research, chair of internal medicine III, University Hospital Erlangen, Friedrich-Alexander University, Germany
- Peter A. Merkel, M.D., MPH, chief, division of rheumatology, professor of medicine and professor of epidemiology in biostatistics and epidemiology, University of Pennsylvania
- David Jayne, M.D., professor of clinical autoimmunity, University of Cambridge, U.K., director of the Vasculitis and Lupus Service, Addenbrooke’s Hospital
- Carlotta Cacciatore, M.D., Centre de Référence des Maladies Auto-immunes Systémiques Rares d’Ile-de-France, Hôpital Saint Louis, France
- Peter Maag, Ph.D., CEO of Kyverna
- Dominic Borie, M.D., Ph.D., president of R&D at Kyverna
About Lupus Nephritis (LN)
About Kyverna Therapeutics
Kyverna Therapeutics is a cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna’s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. By offering more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated. For more information, please visit https://kyvernatx.com.
Greig Communications, Inc.
- E. Carter et al., Nature Reviews Rheumatology, 12, Oct. 2016, 605-620.
- Adv Chronic Kidney Dis. 2019;26(5):313.
- Brudno et al., Nature Medicine 2020; 26:270-280.